For the most part, developing new medical technologies is a huge benefit to people. Take for instance the smart pill that the U.S. Food and Drug Administration (FDA) just approved, which is meant to monitor if patients are sticking to their medication schedule. While incredibly useful, it could also allow entities like the U.S. government to spy on its citizens even more intrusively than it does now.
No one likes to be spied on and yet this is exactly what concerned privacy groups are saying could happen with the digital pill that the FDA just approved for use. Called the Abilify MyCite, the pill comes with sensors that basically indicate if patients just took their medication, Futurism reports.
Abilify is a drug used to treat neurological conditions such as schizophrenia and bipolar disorders. The sensor is embedded in the pill, where it will send out a signal once it comes in contact with the stomach. This signal will be picked up by a patch on the patient’s left rib cage, which will then notify the monitoring personnel via the accompanying app.
The information that the sensors can send out can include the dosage, the exact time when the pill was taken, and even what the patient was doing at the time. Because of how intrusive the data mining process appears, groups concerned about potential abuses are speaking out. They are especially worried about potential punitive actions against patients who are committing what’s called nonadherence.
Basically, nonadherence or noncompliance refers to patients not taking their medication as they are supposed to. This leads to patients getting sicker, which then leads to higher medical costs due to the increased medical attention that they need. Apparently, this particular trend costs $100 billion a year, the New York Times reports.
There’s also the concern of medical professionals that a smart pill could lead to a feeling of coercion on the part of the patients. Subjects could feel pressured to take their medication because their doctors are monitoring them.


Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Instagram Outage Disrupts Thousands of U.S. Users
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Tabletop particle accelerator could transform medicine and materials science
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



